Endo International PLC (ENDP) Rating Reiterated by BMO Capital Markets
Endo International PLC (NASDAQ:ENDP)‘s stock had its “hold” rating reaffirmed by investment analysts at BMO Capital Markets in a report issued on Friday.
Other equities research analysts have also recently issued reports about the company. Vetr cut Endo International PLC from a “strong-buy” rating to a “buy” rating and set a $18.57 price objective on the stock. in a research note on Tuesday, August 2nd. JPMorgan Chase & Co. set a $40.00 price objective on Endo International PLC and gave the company a “buy” rating in a research note on Tuesday, August 9th. Mizuho upgraded Endo International PLC from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $16.00 to $29.00 in a research note on Friday, August 12th. Citigroup Inc. lowered their price objective on Endo International PLC from $40.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, September 16th. Finally, Guggenheim restated a “buy” rating and issued a $35.00 price objective on shares of Endo International PLC in a research note on Saturday, October 15th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. Endo International PLC currently has an average rating of “Buy” and a consensus price target of $31.63.
Endo International PLC (NASDAQ:ENDP) opened at 18.19 on Friday. The stock has a 50 day moving average of $19.47 and a 200-day moving average of $18.84. The company’s market cap is $4.05 billion. Endo International PLC has a 12-month low of $12.56 and a 12-month high of $63.71.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Tuesday, November 8th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.20. Endo International PLC had a positive return on equity of 15.95% and a negative net margin of 3.32%. The business had revenue of $894.30 million for the quarter, compared to analysts’ expectations of $862.47 million. During the same period in the previous year, the business posted $1.02 EPS. The firm’s quarterly revenue was up 18.6% compared to the same quarter last year. On average, equities research analysts anticipate that Endo International PLC will post $4.59 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in ENDP. Acrospire Investment Management LLC increased its position in shares of Endo International PLC by 139.3% in the third quarter. Acrospire Investment Management LLC now owns 7,897 shares of the company’s stock worth $159,000 after buying an additional 4,597 shares in the last quarter. Canada Pension Plan Investment Board increased its position in shares of Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock worth $254,000 after buying an additional 2,237 shares in the last quarter. LS Investment Advisors LLC increased its position in shares of Endo International PLC by 152.3% in the second quarter. LS Investment Advisors LLC now owns 13,661 shares of the company’s stock worth $213,000 after buying an additional 8,247 shares in the last quarter. Icon Advisers Inc. Co. acquired a new position in shares of Endo International PLC during the second quarter worth approximately $218,000. Finally, IFP Advisors Inc increased its position in shares of Endo International PLC by 103,542.9% in the second quarter. IFP Advisors Inc now owns 14,510 shares of the company’s stock worth $226,000 after buying an additional 14,496 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.